Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03709641 · ClinicalTrials.gov registry record · NA
A Study to Evaluate the Safety and Effectiveness of Restylane-Defyne for Punctual Occlusion
A NA study, sponsored by John C Meyer, MD.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT03709641: Completed NA study, sponsored by John C Meyer, MD.
NCT03709641 is a NA study that has completed, run by John C Meyer, MD. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03709641, a NA study, has completed, sponsored by John C Meyer, MD.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
A study which participants with mild to moderate dry eye disease will have a punctum of one eye injected with Restyalne Defyne and the other eye injected with saline solution. Participants will be evaluated over four visits.
Primary Outcome
Maximum length of tears absorbed on test strips recorded.
Interventions
- DEVICE Restylane Defyne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-10-17 |
| Est. Completion | 2018-11-28 |
| Phase | NA |
What the finished NCT03709641 record still lists
NCT03709641 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Restylane Defyne is the first listed.
NCT03709641 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03709641 about?
NCT03709641 is a clinical study titled "A Study to Evaluate the Safety and Effectiveness of Restylane-Defyne for Punctual Occlusion". A study which participants with mild to moderate dry eye disease will have a punctum of one eye injected with Restyalne Defyne and the other eye injected with saline solution. Participants will be evaluated over four visits.
What is the current status of trial NCT03709641?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2018-10-17. Estimated completion is 2018-11-28.
What interventions are being tested in trial NCT03709641?
The interventions under investigation include: Restylane Defyne (DEVICE).
Who is sponsoring clinical trial NCT03709641?
This trial is sponsored by John C Meyer, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03709641's enrollment target sits among peer trials
14 1909th of 2000 higher than 90 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy